BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21739101)

  • 1. The effect of delays in treatment for breast cancer metastasis on survival.
    Jung SY; Sereika SM; Linkov F; Brufsky A; Weissfeld JL; Rosenzweig M
    Breast Cancer Res Treat; 2011 Dec; 130(3):953-64. PubMed ID: 21739101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with mortality after breast cancer metastasis.
    Jung SY; Rosenzweig M; Sereika SM; Linkov F; Brufsky A; Weissfeld JL
    Cancer Causes Control; 2012 Jan; 23(1):103-12. PubMed ID: 22037907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer.
    Richards MA; Smith P; Ramirez AJ; Fentiman IS; Rubens RD
    Br J Cancer; 1999 Feb; 79(5-6):858-64. PubMed ID: 10070881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metastases in breast cancer: prognostic factors and management.
    Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
    Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
    Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME
    Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3337-43. PubMed ID: 16740755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fifteen-year trends in metastatic breast cancer survival in Greece.
    Dafni U; Grimani I; Xyrafas A; Eleftheraki AG; Fountzilas G
    Breast Cancer Res Treat; 2010 Feb; 119(3):621-31. PubMed ID: 19915976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer with synchronous metastases: trends in survival during a 14-year period.
    Andre F; Slimane K; Bachelot T; Dunant A; Namer M; Barrelier A; Kabbaj O; Spano JP; Marsiglia H; Rouzier R; Delaloge S; Spielmann M
    J Clin Oncol; 2004 Aug; 22(16):3302-8. PubMed ID: 15310773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
    Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP
    Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of metastatic spread in triple-negative breast cancer.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.